logo

Evofem Biosciences Inc. (EVFM)



Trade EVFM now with
  Date
  Headline
11/22/2021 6:51:30 AM Evofem Biosciences Says Successfully Extends Cumulative Net Sales Covenant Timing To June 30, 2023
11/10/2021 7:13:45 AM Evofem Biosciences Announces Regulatory Submission In Mexico For Hormone-Free Contraceptive
9/27/2021 8:16:21 AM Evofem : Manuscript On Variability Of Contraceptive Trial Design And Impact On Efficacy Outcomes Published
9/16/2021 8:12:08 AM Evofem Biosciences To Present Seven Abstracts On Vaginal PH Modulator
5/21/2021 6:52:31 AM Evofem Biosciences Reports Closing Of $50 Mln Public Offering
5/17/2021 11:15:49 PM Evofem Biosciences Announces Pricing Of $50 Mln Public Offering
5/17/2021 9:38:47 AM Evofem To Present New Data On EVO100 For The Prevention Of Chlamydia And Gonorrhea In Women
3/24/2021 10:18:29 PM Evofem Biosciences Prices Underwritten Public Offering Of 17.14 Mln Shares At $1.75/shr
3/16/2021 8:11:42 AM Evofem Biosciences Publishes Pivotal Manuscript From AMPREVENCE Trial In American Journal Of Obstetrics And Gynecology
3/4/2021 4:05:41 PM Evofem Biosciences Q4 Loss/share $0.50 Vs. Loss $0.27 Year Ago
12/17/2020 7:43:25 AM Evofem Biosciences Updates On Pivotal Phase 3 Trial Of EVO100 For Prevention Of Chlamydia And Gonorrhea
10/20/2020 8:12:42 AM Evofem Says First Patient Enrolled In Pivotal Phase 3 Trial Of EVO100 For Prevention Of Chlamydia And Gonorrhea
10/15/2020 8:03:19 AM Evofem Biosciences Sells $25 Mln Of Unsecured Convertible Promissory Notes To Funds Affiliated With Adjuvant Capital, LP